文献速递胃肠外科

机器人完整结肠系膜切除术治疗右半结肠癌安全可行:单中心短期与中期结果

Robotic Complete Mesocolic Excision (CME) is a safe and feasible option for right colonic cancers: short and midterm results from a single-centre experience.
PubMed 文献 · Surg Endosc · 2021-01-05

中位手术时间180分钟,中位失血量10ml,无中转开腹,中位淋巴结30枚,R1切除3例(4%),无30天或90天死亡,3年无病生存率I期100%、II期91.7%、III期92%,总生存率94%。结论认为机器人CME可行、有效且安全。

要点

  • 标准化机器人CME(SMV优先入路)右半结肠癌中转开腹率为0,无30天或90天死亡。
  • 中位淋巴结检出30枚,R1切除率4%,III期局部复发1例(1%)。
  • 3年无病生存率I期100%、II期91.7%、III期92%,总生存率94%。

核心结论

  • 机器人CME治疗右半结肠癌可行、有效且安全,在该标准化入路队列中观察到良好的肿瘤学结果和生存改善。

主要发现

  • 中位手术时间180(128-454)分钟,围手术期失血量10(10-50)ml,25例有腹部手术史。
  • 中位术后住院5(3-18)天,本组无中转开腹。
  • 中位淋巴结计数30(10-60)枚,3例(4%)R1切除。
  • III期疾病局部复发1例(1%),II期和III期远端复发4例(5%)。
  • 无30天或90天死亡;3年无病生存率I期100%、II期91.7%、III期92%,总生存率94%。

临床怎么用

  • 在具备机器人平台和标准化CME技术(SMV优先入路)的中心,可考虑将机器人CME用于右半结肠癌。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Complete mesocolic excision (CME) for right colon cancers has traditionally been an open procedure. Surgical adoption of minimal access CME remains limited due to the technical challenges, training gaps and lack of level-1 data for proven benefits. Currently there is limited published data regarding the clinical results with the use of robotic CME surgery. Aim To report our experience, results and techniques, highlighting a clinical and oncological results and midterm oncological outcomes for robotic CME. AIM: To report our experience, results and techniques, highlighting a clinical and oncological results and midterm oncological outcomes for robotic CME. METHODS: All patients undergoing standardised robotic CME technique with SMV first approach between January 2015 and September 2019 were included in this retrospective review of a prospectively collected database. Patient demographics, operative data and clinical and oncological outcomes were recorded. RESULTS: Seventy-seven robotic CME resections for right colonic cancers were performed over a 4-year period. Median operative time was 180 (128-454) min and perioperative blood loss was 10 (10-50) ml. There were 25 patients who had previous abdominal surgery. Median postoperative hospital stay was 5 (3-18) days. There was no conversion to open surgery in this series. Median lymph node count was 30 (10-60). Three (4%) patients had R1 resection. There was one (1%) local recurrence in stage III disease and 4(5%) distal recurrence in stage II and stage III. There was no 30- or 90-day mortality. Three-year disease-free survival was 100%, 91.7% and 92% for stages I, II and III, respectively. Overall survival was 94%. CONCLUSIONS: Robotic CME is feasible, effective and safe. Good oncological results and improved survival are seen in this cohort of patients with a standardised approach to robotic CME.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Siddiqi N, Stefan S, Jootun R, et al. Robotic Complete Mesocolic Excision (CME) is a safe and feasible option for right colonic cancers: short and midterm results from a single-centre experience. Surg Endosc. 2021. PMID: 33399993. doi:10.1007/s00464-020-08194-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。